The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
“This difference was attributed to the elevated expression of FUT8, the gene coding for a1,6-fucosyltransferase, in the CHO line (Shinkawa et al., 2003).”
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
“For example several approaches have been shown to enhance the ability of an antibody to mediate antibody-dependent cell-mediated cytotoxicity by optimizing the structure of the Fc-associated N-linked oligosaccharide (2, 3).”
BackgroundPotent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
“Reducing the fucose content increases ADCC activity to a greater extent than does increasing the presence of bisecting N -acetylglucosamin”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Antibody Structure, Instability, and Formulation
Wang, W., Singh, S., Zeng, D. L., King, K., & Nema, S. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20727 · Cited by 941
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
“Recombinant antibodies lacking fucose show enhanced FcγR binding and ADCC”
BackgroundTherapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
“Decreasing the fucose content of the carbohydrates in the Fc region can also enhance ADC”
BackgroundGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
“In particular, a next generation of anticancer antibodies carrying afucosylated glycoforms (13, 14) is currently in clinical development; the most advanced among these is the glycoengineered CD20 antibody obinutuzumab (GA101), currently in phase II/III clinical trials for treatment of non-Hodgkin’s lymphoma and chroni…”
BackgroundIshida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
“Such mAbs may be produced using different methods reported to lead to the successful expression of relatively low level fucosylated antibodies bearing the biantennary complex-type of Fc oligosaccharides, such as the control of culture osmolality [411], application of a variant CHO line Lec13 as the host cell line [412…”
BackgroundKolbeck, R., Kozhich, A., Koike, M., Peng, L., Andersson, C. K., Damschroder, M. M., Reed, J. L., Woods, R., Dall'Acqua, W. W., Stephens, G. L., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.004 · Cited by 586
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
“Second, chromosomal abnormalities, which significantly affect the copynumber and chromosome location of the target loci (Prouty et al., 1993), have been found to accumulate in CHO cells (Siciliano et al., 1985; Warner, 1999).”
BackgroundSelf-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 559
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2008) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526
Pučić, M., Knežević, A., Vidič, J., Adamczyk, B., Novokmet, M., Polašek, O., Gornik, O., Šupraha-Goreta, S., Wormald, M. R., Redžić, I., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.010090 · Cited by 524
Strasser, R., Stadlmann, J., Schähs, M., Stiegler, G., Quendler, H., Mach, L., Glössl, J., Weterings, K., Pabst, M., & Steinkellner, H. (2008) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2008.00330.x · Cited by 520
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
“This was subsequently achieved by modifying the amino acid sequence in the Fc domain or by de-fucosylation of the N-linked oligosaccharides on the Fc region (Shinkawa et al, 2003; Stavenhagen et al, 2008).”
Wang, X., Inoue, S., Gu, J., Miyoshi, E., Noda, K., Li, W., Mizuno-Horikawa, Y., Nakano, M., Asahi, M., Takahashi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507375102 · Cited by 476
Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 469
“The presence of a bisecting N-acetylglucosamine (Umana et al. 1999; Davies et al. 2001) or the absence of fucose (Shields et al. 2002; Shinkawa et al. 2003; Okazaki et al. 2004) in the conserved glycan of an IgG antibody has been shown to enhance attachment to Fc receptors and result in an increase…”
BackgroundBiological functions of fucose in mammals
Schneider, M., Al-Shareffi, E., & Haltiwanger, R. S. (2017) · Glycobiology · doi:10.1093/glycob/cwx034 · Cited by 431
“This observation is of particular importance because therapeutic antibodies, used in the treatment of cancer and other diseases, can be generated without this core fucose to significantly enhance their potency (Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundLiu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Optimization of humanized IgGs in glycoengineered Pichia pastoris
Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.-K., Cook, W. J., Cukan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1178 · Cited by 428
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R., Frantz, K. K., Peele, C. G., Black, A., Passmore, D., Moldovan-Loomis, C., Srinivasan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1260 · Cited by 421
“Both ADCC activity and FcR binding are highly dependent on the presence and type of N -glycan structures attached to the mAb heavy chai”
BackgroundFc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Plant‐specific glycosylation patterns in the context of therapeutic protein production
Gomord, V., Fitchette, A., Menu‐Bouaouiche, L., Saint‐Jore‐Dupas, C., Plasson, C., Michaud, D., & Faye, L. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2009.00497.x · Cited by 418
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
“However, whether this is just a consequence of the decreased level of core fucosylation that accompanies bisection remains controversial [142].”
BackgroundProduction of Complex Human Glycoproteins in Yeast
Hamilton, S. R., Bobrowicz, P., Bobrowicz, B., Davidson, R. C., Li, H., Mitchell, T., Nett, J. H., Rausch, S., Stadheim, T. A., Wischnewski, H., et al. (2003) · Science · doi:10.1126/science.1088166 · Cited by 407
Functional roles of N‐glycans in cell signaling and cell adhesion in cancer
Zhao, Y., Takahashi, M., Gu, J., Miyoshi, E., Matsumoto, A., Kitazume, S., & Taniguchi, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00839.x · Cited by 405
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
“Therefore, a thorough characterization of carbohydrate content, the structure of the carbohydrate chain, the oligosaccharides and glycosylation sites present on the antibody is critical (Shinkawa et al. 2003).”
InfluentialScallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Biological Function of Fucosylation in Cancer Biology
Miyoshi, E., Moriwaki, K., & Nakagawa, T. (2007) · Journal of Biochemistry · doi:10.1093/jb/mvn011 · Cited by 395
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393
“In fact, a recent study based on Rituxan has suggested that it is lack of a core fucose and not the presence of a bisecting GlcNAc that is effective in increasing Mab ADCC activity [ 6 ].”
BackgroundHuman antibody–Fc receptor interactions illuminated by crystal structures
Woof, J. M., & Burton, D. R. (2004) · Nature Reviews Immunology · doi:10.1038/nri1266 · Cited by 387
“For example, the absence of fucose residues from IgG Fc-region carbohydrates is associated with improved binding to FcγRIII and enhanced ADC”
BackgroundExpression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386
Taniguchi (2015) · doi:10.1016/bs.acr.2014.11.001 · Cited by 381
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
“Two antibody-producing clones, Lec13 A4 and Ms704 1A715, transformed by the antihuman CD20 mouse/human chimeric IgG1 (equivalent to rituximab) expression vector pKANTEX2B8P (Shinkawa et al. 2003), were established as described previously (Kanda et al.”
BackgroundMethodInfluentialSelf-citationHigel, F., Seidl, A., Sörgel, F., & Friess, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.005 · Cited by 360
Characterizing biological products and assessing comparability following manufacturing changes
Chirino, A. J., & Mire-Sluis, A. (2004) · Nature Biotechnology · doi:10.1038/nbt1030 · Cited by 364
Ogura, M., Ishida, T., Hatake, K., Taniwaki, M., Ando, K., Tobinai, K., Fujimoto, K., Yamamoto, K., Miyamoto, T., Uike, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0924 · Cited by 362
Lauc, G., Huffman, J. E., Pučić, M., Zgaga, L., Adamczyk, B., Mužinić, A., Novokmet, M., Polašek, O., Gornik, O., Krištić, J., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003225 · Cited by 361
Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity
Ackerman, M. E., Crispin, M., Yu, X., Baruah, K., Boesch, A. W., Harvey, D. J., Dugast, A.-S., Heizen, E. L., Ercan, A., Choi, I., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65708 · Cited by 358
“This association was surprising in that increased galactosylation has tended to drive better ADCC in recombinantly produced monoclonal antibodies (26).”
BackgroundDekkers, G., Treffers, L., Plomp, R., Bentlage, A. E. H., de Boer, M., Koeleman, C. A. M., Lissenberg-Thunnissen, S. N., Visser, R., Brouwer, M., Mok, J. Y., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00877 · Cited by 356
“The prototypic variation of this kind are glyco-engineered IgG1 antibodies without fucose with elevated FcγRIIIa affinities (4, 5), which have already found its way to therapeutic antibodies on the market (6).”
BackgroundIgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
“This article is an open access publication P ro te in & C e ll compared to antibodies containing bisectingGlcNAc (Shinkawa et al., 2003).”
BackgroundThe Carbohydrate at FcγRIIIa Asn-162
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 354
Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., Yamaguchi, K., Yamada, Y., Hanada, S., Tamura, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3575 · Cited by 354
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
“In fact, non-fucosylated antibodies, produced in cells lacking the fucosyl transferase, bind to FcγRIIIa with an enhanced affinity and are thereby able to induce increased ADC”
BackgroundOkazaki, A., Shoji-Hosaka, E., Nakamura, K., Wakitani, M., Uchida, K., Kakita, S., Tsumoto, K., Kumagai, I., & Shitara, K. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.007 · Cited by 337
Self-citationPereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
“In a female patient with metastatic HER2C colorectal cancer against which all other options failed, the use of TrasGEX resulted in a 10-fold to 140-fold enhanced ADCC.128 SEA-CD40 is a humanized afucosylated anti-CD40 IgG1 developed by Seattle Genetics.”
BackgroundResultInfluentialRecombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 330
Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai, N., & Shitara, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2068 · Cited by 325
“Compared with fucose, the involvement of bisecting-GlcNAc in ADCC was minimal, and galactose did not contribute to ADCC (16).”
BackgroundMethodInfluentialSelf-citationModulating IgG effector function by Fc glycan engineering
Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L.-X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 322
“These results agree with the enhanced FcγRIIIA affinity by our afucosylated glycovariants (Tables 1 and 2), are consistent with all previous reports for afucosylated antibodies (25, 26), and confirm the results of ADCC assays for sialylated/ afucosylated antibodies reported recently by Lin et al.”
ResultThe Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 323
Core Fucosylation Regulates Epidermal Growth Factor Receptor-mediated Intracellular Signaling
Wang, X., Gu, J., Ihara, H., Miyoshi, E., Honke, K., & Taniguchi, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510893200 · Cited by 323
Takatsu, K., & Nakajima, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.04.001 · Cited by 320
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
“Despite these results the importance of bisecting GlcNAc is debated, and the removal of fucose has been asserted as an alternative hypothesis [Figure 2B; (74)].”
BackgroundMass spectrometry for structural characterization of therapeutic antibodies
Zhang, Z., Pan, H., & Chen, X. (2009) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 316
High-sensitivity Analytical Approaches for the Structural Characterization of Glycoproteins
Alley, W. R., Mann, B. F., & Novotny, M. V. (2013) · Chemical Reviews · doi:10.1021/cr3003714 · Cited by 310
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Interleukin-5 and IL-5 receptor in health and diseases
TAKATSU, K. (2011) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.87.463 · Cited by 297
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002; Shinkawa et al., 2003; Niwa et al., 2005; Iida et al., 2006; Subedi and Barb, 2016).”
BackgroundAlt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
“These activities are critically dependent on IgG-Fc N-linked glycosylation and, in part, on individual antibody glycoforms [3,13-20] .”
BackgroundRombouts, Y., Ewing, E., van de Stadt, L. A., Selman, M. H. J., Trouw, L. A., Deelder, A. M., Huizinga, T. W. J., Wuhrer, M., van Schaardenburg, D., Toes, R. E. M., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203565 · Cited by 288
Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 284
Antibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285
“Indeed, previous studies with IgG glycovariants lacking branching fucose residues showed that the absence of this single sugar residue dramatically increased the affinity of IgG for selective activating FccRs and their pro-inflammatory activity (50, 87, 88).”
BackgroundStructural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
Matsumiya, S., Yamaguchi, Y., Saito, J.-I., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K., & Kato, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.034 · Cited by 278
“L-[13C6, 15N4]Arg was from ISOTEC. βGalactosidase (Streptococcus 6646K) was from Seikagaku Corp. Establishment of human IgG1-producing cell lines The Chinese hamster ovary (CHO)/DG44 cell line46 was kindly provided by Dr. Lawrence Chasin (Columbia University, NY). pKANTEX2160, an expression vector encoding an anti-CCR…”
MethodSelf-citationPhage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Kimura, H., Sakai, K., Arao, T., Shimoyama, T., Tamura, T., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00510.x · Cited by 277
Structure, heterogeneity and developability assessment of therapeutic antibodies
Xu, Y., Wang, D., Mason, B., Rossomando, T., Li, N., Liu, D., Cheung, J. K., Xu, W., Raghava, S., Katiyar, A., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1553476 · Cited by 264
Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer
Chen, C.-Y., Jan, Y.-H., Juan, Y.-H., Yang, C.-J., Huang, M.-S., Yu, C.-J., Yang, P.-C., Hsiao, M., Hsu, T.-L., & Wong, C.-H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220425110 · Cited by 266
“For example, deletion of the core fucose from the Fc region of IgG1 greatly improves its binding affinity to Fcγ receptor IIIa, which in turn enhances antibody-dependent cell-mediated cytotoxicity for over 50 folds (5, 6).”
BackgroundIshida, T., Jo, T., Takemoto, S., Suzushima, H., Uozumi, K., Yamamoto, K., Uike, N., Saburi, Y., Nosaka, K., Utsunomiya, A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13338 · Cited by 267
Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum
Wuhrer, M., Stam, J. C., van de Geijn, F. E., Koeleman, C. A. M., Verrips, C. T., Dolhain, R. J. E. M., Hokke, C. H., & Deelder, A. M. (2007) · PROTEOMICS · doi:10.1002/pmic.200700289 · Cited by 263
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies
Mueller, A.-L., Payandeh, Z., Mohammadkhani, N., Mubarak, S. M. H., Zakeri, A., Alagheband Bahrami, A., Brockmueller, A., & Shakibaei, M. (2021) · Cells · doi:10.3390/cells10113017 · Cited by 256
“Galactosylation and sialylation are both key players in the regulation of the antibody effector function [87,90].”
BackgroundAgalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity
Nimmerjahn, F., Anthony, R. M., & Ravetch, J. V. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702936104 · Cited by 253
CCR4 as a novel molecular target for immunotherapy of cancer
Ishida, T., & Ueda, R. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00307.x · Cited by 247
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Mizushima, T., Yagi, H., Takemoto, E., Shibata‐Koyama, M., Isoda, Y., Iida, S., Masuda, K., Satoh, M., & Kato, K. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2011.01552.x · Cited by 245
“…Biology Society of Japan/Blackwell Publishing Ltd. 1071 (>50-fold) of antibody-dependent cellular cytotoxicity (ADCC) through improved IgG binding to Fcc receptor IIIa (FccIIIa) (Shields et al. 2002; Shinkawa et al. 2003; Taniguchi et al. 2006; Kubota et al. 2009; Yamane-Ohnuki & Satoh 2009).”
BackgroundSelf-citationIshii, T., Ishida, T., Utsunomiya, A., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Imada, K., Uchiyama, T., Akinaga, S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2697 · Cited by 246
“Accordingly, we have developed a chimeric anti-CCR4 mAb, KM2760 (7), the Fc region of which is defucosylated, resulting in highly enhanced antibody-dependent cellular cytotoxicity (ADCC) due to increased binding affinity to the Fcγ receptor (FcγR) on effector cells (8, 9).”
BackgroundSelf-citationNiwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.08.009 · Cited by 244
Self-citationFc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Liu, R., Oldham, R., Teal, E., Beers, S., & Cragg, M. (2020) · Antibodies · doi:10.3390/antib9040064 · Cited by 238
“Another method for generating afucosylated antibodies stemmed from a study in 2003, showing that humanized antibodies generated in a rat hybridoma YB2/0 cell line had 50-fold higher ADCC activity compared to those produced in CHO cell lines (Figure 1A) [63].”
BackgroundResultPharmacokinetics and toxicology of therapeutic proteins: Advances and challenges
Vugmeyster, Y. (2012) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v3.i4.73 · Cited by 242
Branched N‐glycans regulate the biological functions of integrins and cadherins
Zhao, Y., Sato, Y., Isaji, T., Fukuda, T., Matsumoto, A., Miyoshi, E., Gu, J., & Taniguchi, N. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06346.x · Cited by 236
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236
“…oligosaccharides modified by bisecting GlcNAc, a β1,4-GlcnAc residue attached to a core β-mannose residue, or lack the core fucose of the Fc oligosaccharides and have been found to exhibit significantly higher ADCC than their unmodified counterparts (Lifely et al., 1995; Shinkawa et al., 2003).”
BackgroundInfluentialAntibodies, Fc receptors and cancer
Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 234
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Duvic, M., Pinter-Brown, L. C., Foss, F. M., Sokol, L., Jorgensen, J. L., Challagundla, P., Dwyer, K. M., Zhang, X., Kurman, M. R., Ballerini, R., et al. (2015) · Blood · doi:10.1182/blood-2014-09-600924 · Cited by 230
“Removal of fucose results in the antibody eliciting more potent antibody-dependent cellular cytotoxicity than conventionally produced antibodies.(18,19)Mogamulizumab bindswith high affinity to theN-terminal domain of CCR4, but is not internalized and does not exhibit complement-dependent cytotoxic activity or directly…”
BackgroundPharmacological significance of glycosylation in therapeutic proteins
Li, H., & d’Anjou, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.009 · Cited by 231
“Carbohydrate heterogeneity, particularly core fucosylation or the presence of bisecting N-acetylglucosamine, is known to modulate the activity of effector cells in the blood and of the antibody to affect NK cell-mediated killing [6,7,41–43,44 ].”
BackgroundGlycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
Hudak, J. E., & Bertozzi, C. R. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.010 · Cited by 231
“This has led to continued efforts to produce nonfucosylated antibodies with enhanced Fc receptor binding (Satoh et al., 2006; Shields et al., 2002; Shinkawa et al., 2003; Zhou et al., 2008).”
BackgroundN-glycomic biomarkers of biological aging and longevity: A link with inflammaging
Dall’Olio, F., Vanhooren, V., Chen, C. C., Slagboom, P. E., Wuhrer, M., & Franceschi, C. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.02.002 · Cited by 231
“…modulated by the 2,6-sialylation Krapp et al., 2003; Scallon et al., 2007) and by core fucosylaion (Niwa et al., 2005; Shields et al., 2002; Shinkawa et al., 2003; atoh et al., 2006; Iida et al., 2009; Shibata-Koyama et al., 2009; ida et al., 2006) and positively modulated by bisecting…”
BackgroundInfluentialNiwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227
“This results in KM3065 exhibiting much higher ADCC than rituximab (14).”
BackgroundMethodSelf-citationImpact of host cell line choice on glycan profile
Goh, J. B., & Ng, S. K. (2018) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1416577 · Cited by 225
“(ADCC) was increased in fucose-deficient IgG [9,10].”
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W. K., Dechant, M., Beyer, T., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 222
Scherer, H. U., van der Woude, D., Ioan‐Facsinay, A., el Bannoudi, H., Trouw, L. A., Wang, J., Häupl, T., Burmester, G., Deelder, A. M., Huizinga, T. W. J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27414 · Cited by 223
“In the absence of core fucose residues, ADCC is significantly increased (12,14,37).”
Background
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.